A urologist discusses treatments in the pipeline that can further improve the therapeutic landscape in BCG-unresponsive NMIBC.
This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.
Shore emphasizes the exciting developments in bladder cancer, including multiple new treatment approaches. Beyond the therapies already discussed, he highlights promising viral gene vectors like CG0070 to stimulate antitumor immunity when given intravesically.
For muscle invasive bladder cancer, efforts to spare the bladder are progressing with novel additions like intravesical devices or immunotherapy to enhance efficacy. The combination of enfortumab vedotin and pembrolizumab produced notable results for first-line metastatic disease in the phase 3 EV-302 trial, supporting study of this regimen in other settings like neoadjuvant therapy.
Finally, for non–muscle invasive disease, combining emerging strategies with BCG could synergize effects. Across settings from BCG-unresponsive high-risk non–muscle invasive bladder cancer to frontline metastatic disease, Dr Shore conveys excitement for the rapid evolution in bladder cancer research and care.
Video synopsis is AI generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.